{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'LIST OF TABLES', 'PAGE', 'Table 1', 'Classification of severity of airflow limitation in COPD (based on', 'post-bronchodilator FEV1)', '27', 'Table 2', 'Classification of severity of AECOPD', '29', 'Table 3', 'Study groups and epochs foreseen in the study', '33', 'Table 4', 'List of study procedures for scheduled visits', '41', 'Table 5', 'List of study procedures for AECOPD visits', '43', 'Table 6', 'Intervals between study visits', '43', 'Table 7', 'Biological samples', '55', 'Table 8', 'Microbiology', '57', 'Table 9', 'Planned assays on serological samples', '58', 'Table 10', 'Reporting period for SAE and AEs leading to withdrawal', '(Amended 19 October 2018)', '61', 'Table 11', 'Timeframes for submitting SAEs related to study participation to', 'GSK', '63', 'Table 12', 'Exact 95% confidence intervals of the percentage of occurrence', 'of a specific bacterium from sputum collected during AECOPD', '67', 'Table 13', '95% confidence intervals of AECOPD incidence rates with', 'different overdispersion values', '68', 'Table 14', \"GSK Biologicals' laboratories\", '78', 'Table 15', 'Outsourced Laboratories', '78', '19-OCT-2018', '17', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'LIST OF FIGURES', 'PAGE', 'Figure 1', 'The refined ABCD assessment tool', '27', 'Figure 2', 'Study design overview', '32', '19-OCT-2018', '18', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'LIST OF APPENDICES', 'PAGE', 'APPENDIX A CLINICAL LABORATORIES (Amended 19 October 2018)', '78', 'APPENDIX B AMENDMENT TO THE PROTOCOL', '79', '19-OCT-2018', '19', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}